What are the odds of being diagnosed with HIV in your lifetime?
Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
● your factors — click this risk ▾ to reveal
- Your factors
≈ As likely as
Perceived
There is no standard tracker for perceived personal lifetime HIV risk, so the perceived side here is editorial intuition rather than polled data. Lay perception is distorted in two opposite directions at once. The 1980s-90s framing of HIV as a uniform death sentence still anchors the felt severity, even though a US adult diagnosed and treated today has a near-normal life expectancy on antiretroviral therapy. At the same time, personal probability is widely underestimated by the groups who actually carry elevated risk, via ordinary optimism bias and the sense that HIV is "someone else's" problem. The result is a population that overestimates how bad a diagnosis is and, in the higher-risk subgroups, underestimates how likely one is. The single national-average number is almost useless here: the same headline figure hides a 250-fold spread between subgroups.
Rough estimate: most people treat HIV as either near-zero personal risk or a uniform catastrophe; both miss the subgroup spread
Source: editorial intuition, not polled
Actual
0.95% lifetime risk of HIV diagnosis (~1 in 106), US 2010-2014
US general population, hypothetical birth cohort, CDC surveillance data 2010-2014
Show derivation
Headline figure is the published, peer-reviewed Hess et al. 2017 estimate in Annals of Epidemiology: overall lifetime risk of an HIV diagnosis of 0.95% (95% CI 0.94-0.95), equivalently ~1 in 106, computed from CDC mortality, census, and HIV surveillance data for 2010-2014. The earlier, more frequently cited "1 in 99" figure is the same CDC research line at the prior 2009-2013 data window (presented at CROI 2016); the lifetime risk has declined monotonically — about 1 in 78 for 2004-2005, 1 in 99 for 2009-2013, and 1 in 106 for 2010-2014. We anchor on the published peer-reviewed window to keep the statistic, excerpt, and normalized number mutually consistent. Hess et al. compute lifetime risk as a birth-cohort cumulative probability (a hypothetical 10-million-birth cohort) assuming diagnosis rates stay constant. For HIV this is nearly identical to a from-age-18 US-adult lifetime basis, because almost no diagnosis risk accrues before adulthood and perinatal cases are a small fraction; the two bases are treated as equivalent here. The uncertainty band 0.008-0.013 brackets the post-2014 decline (new US infections fell to ~31,800 by 2022) on the low end and the 2004-2005-era figure on the high end. This national average is a scale marker only — the entry's point is the subgroup variance documented below, which ranges from roughly 1 in 524 (heterosexual men) to 1 in 2 (Black men who have sex with men).
Caveats: The headline 0.95% (~1 in 106) is a national-average lifetime risk projected fro…
The headline 0.95% (~1 in 106) is a national-average lifetime risk projected from 2010-2014 CDC surveillance assuming diagnosis rates hold constant — not a current snapshot, and the rate has continued to decline (US new infections fell to ~31,800 by 2022). The far more important caveat is heterogeneity: the average is the least informative number in this entry. Lifetime risk spans more than two orders of magnitude across subgroups — roughly 1 in 524 for heterosexual men, 1 in 2 for Black men who have sex with men — and across geography, from about 1 in 674 in the lowest-incidence states to about 1 in 17 in Washington, DC. The published paper measures the probability of a diagnosis, which lags actual infection; undiagnosed infections are not fully captured. Race/ethnicity multipliers reflect structural and network factors (testing access, treatment-as-prevention coverage, partner-pool prevalence), not individual behavior, and should be read as epidemiological strata rather than personal traits. The protective multipliers (condoms ~0.2, PrEP ~0.01) are route-specific and assume correct, consistent use; the PrEP figure is a best-case adherence number. With modern antiretroviral therapy a diagnosed US adult who stays in care has a near-normal life expectancy and is effectively non-infectious (undetectable = untransmittable), which is why this entry is filed as a chronic illness rather than a fatal outcome.
How the risk varies
The headline figure averages across very different situations. Here’s how the probability varies by scenario or context:
1 in 105
Hess et al. 2017, overall lifetime risk of HIV diagnosis, 2010-2014 data (0.95%).
1 in 56 · 1.8%
The South carries the highest burden: 49% of the 31,800 new US infections in 2022 (CDC), with a 2022 diagnosis rate of 506.5 per 100,000 vs 131.6 in the Midwest. The highest published state lifetime risks (mostly Southern) were Maryland (1 in 56), Georgia (1 in 57), Florida and Louisiana (1 in 58); ~1 in 56 (≈0.018) marks those top states, not a South-wide average, which is lower.
1 in 17 · 5.9%
Highest in the US in the published 2010-2014 analysis at 1 in 17 (≈0.059); the earlier 2009-2013 window placed DC at 1 in 13. Reflects a dense urban epidemic, not a typical state.
1 in 667
Published 2010-2014 range bottomed at 1 in 674 (Montana, ≈0.0015); the 2009-2013 window placed North Dakota at 1 in 670. Two-plus orders of magnitude below DC.
Bar length and shade rank these scenarios against each other, not against other risks. The exact odds are shown beside each.
Related risks
Other risks on similar themes — for exploring related fears.
Benzo dependence
What are the odds of developing benzodiazepine dependence after a standard prescription?
Cat litter toxoplasmosis
What are the odds of acquiring a toxoplasma infection from cleaning a cat's litter box?
Childhood cancer diagnosis
What are the odds of a child being diagnosed with cancer before age 20?
Pick challenger
The most carefully measured estimate of lifetime HIV-diagnosis risk in the United States comes from Hess et al. in Annals of Epidemiology (2017): 0.95%, or roughly 1 in 106, based on CDC surveillance data for 2010-2014. The more famous “1 in 99” is the same research line at the earlier 2009-2013 window; the trend has run downward, from about 1 in 78 in 2004-2005 to 1 in 106 by 2014, and US new infections have since fallen further, to about 31,800 in 2022. On its own, that average sits near the lifetime odds of dying from tuberculosis worldwide and just above the lifetime risk of suicide in the US. But for HIV, the average is the least useful number on the page.
The story is the variance. Lifetime risk ranged from 1 in 524 for heterosexual men to 1 in 6 for men who have sex with men, and to 1 in 2 for Black men who have sex with men. Geography moves it almost as much: from roughly 1 in 674 in the lowest-incidence states to about 1 in 17 in Washington, DC. These gaps are not differences in individual behavior so much as differences in the prevalence of the partner pool, testing and treatment access, and network structure. The same data that produce a reassuring national average produce, one stratum over, a near-coin-flip. The other half of the story is that the number is now a lever rather than a fixed fact: CDC reports that pre-exposure prophylaxis, taken as prescribed, reduces sexual-acquisition risk by about 99%, and consistent condom use cuts sexual transmission by roughly 80%.
Where the headline does not apply: it is a birth-cohort projection that assumes constant diagnosis rates, so it neither captures the post-2014 decline nor the undiagnosed fraction, and it measures diagnosis, which lags infection. The race and ethnicity figures are epidemiological strata, not personal attributes, and read most honestly as a map of where prevention resources are and are not reaching. One reframing matters for calibration of severity rather than probability: with modern antiretroviral therapy, a diagnosed US adult who stays in care has a near-normal life expectancy and becomes effectively non-infectious, which is why the outcome measured here is a managed lifelong illness, not the death sentence the 1980s framing still attaches to the three letters.
Related tidbits
The US lifetime HIV-diagnosis risk averages about 1 in 106 — but that average hides a spread from roughly 1 in 524 (heterosexual men) to about 1 in 2 (Black men who have sex with men). Taken as prescribed, PrEP cuts sexual-acquisition risk by around 99%.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Annals of Epidemiology (Hess KL, Hu X, Lansky A, Mermin J, Hall HI) — Lifetime Risk of a Diagnosis of HIV Infection in the United States
Lifetime Risk of a Diagnosis of HIV Infection in the United States- Statistic
Overall lifetime risk of an HIV diagnosis: 0.95% (95% CI 0.94-0.95), ~1 in 106. Lifetime risk 1 in 68 for males and 1 in 253 for females. Highest risk group MSM (1 in 6); lowest male heterosexuals (1 in 524). Data: 2010-2014.- Excerpt
“"Overall, the lifetime risk of a diagnosis of HIV was 0.95% (95% CI: 0.94-0.95)... This means that to observe one HIV diagnosis, 106 (95% CI: 105-106) infants would need to be followed over a lifetime... The lifetime risk for males and females was 1 in 68 and 1 in 253, respectively... The risk group with the highest lifetime risk was MSM (1 in 6)... the lowest risk was among male heterosexuals (1 in 524)." ”
- Source data from
- 2017-04-01
- Accessed
- 2026-06-21 · archived copy
- Calculation
- Hess et al. applied age-specific HIV-diagnosis probabilities from CDC surveillance data for 2010-2014 to a hypothetical cohort of 10 million live births to estimate cumulative lifetime risk. The published overall figure of 0.95% is used directly as the normalized value (0.0095), rounded display "1 in 106". No hazard compounding needed — it is already a lifetime cumulative probability. The male/female split (1/68, 1/253) arithmetically reproduces the overall figure at roughly the US 51/49 sex ratio: 0.51 × (1/68) + 0.49 × (1/253) ≈ 0.0094, an internal-consistency check on the extracted numbers.
- Independence
- Hess et al. (CDC Division of HIV/AIDS Prevention) is the primary peer-reviewed analysis. The CDC HIV surveillance facts-stats page and the CDC PrEP efficacy page below are CDC programmatic outputs drawing on the same surveillance system; they are used as the current-incidence and intervention-efficacy cross-references, not as independent replications of the lifetime estimate.
-
[2] Centers for Disease Control and Prevention (CDC) — HIV Statistics — Facts & Stats
HIV Statistics — Facts & Stats- Statistic
31,800 estimated new HIV infections in the US in 2022; 37,981 new diagnoses. 67% of new infections among gay, bisexual, and other men who have male-to-male sexual contact; 22% heterosexual contact; 7% people who inject drugs. The South accounted for 49% of new infections (rate 506.5 per 100,000) vs 131.6 in the Midwest.- Excerpt
“"There were 31,800 estimated new HIV infections in the US in 2022... Gay, bisexual, and other men who reported male-to-male sexual contact accounted for 67% (21,400) of the 31,800 estimated new HIV infections... 22% were among people who reported heterosexual contact... 7% were among people who inject drugs... In 2022, the South accounted for nearly half (49%) of the 31,800 estimated new HIV infections." ”
- Source data from
- 2024-04-22
- Accessed
- 2026-06-21
- Calculation
- Used as the current-incidence cross-check on the 2010-2014 lifetime projection. The decline to ~31,800 new infections per year by 2022 (from ~37,000-40,000 in the early 2010s) supports placing the lifetime point estimate at the lower end of the historical 1-in-78-to-1-in-106 range and informs the uncertainty band. The transmission-category and regional shares motivate the personal_factor_multipliers and regional_breakdown.
-
[3] Centers for Disease Control and Prevention (CDC) — Pre-Exposure Prophylaxis (PrEP) — HIV Nexus, Clinical Resources
Pre-Exposure Prophylaxis (PrEP) — HIV Nexus, Clinical Resources- Statistic
When taken as prescribed, both oral and injectable PrEP reduce the risk of getting HIV from sex by about 99%. Oral PrEP reduces the risk of getting HIV from injection drug use by at least 74% when taken as prescribed.- Excerpt
“"When taken as prescribed, both oral and injectable PrEP reduce the risk of getting HIV from sex by about 99%... Oral PrEP has also been shown to reduce the risk of getting HIV from injection drug use by at least 74%, when taken as prescribed." ”
- Source data from
- 2026-04-30
- Accessed
- 2026-06-21 · archived copy
- Calculation
- The ~99% sexual-acquisition reduction is the basis for the PrEP protective multiplier of ~0.01 (a roughly 99% reduction in sexual-route risk for adherent users). The 74% injection-route reduction is reported separately. "As prescribed" is load-bearing: real-world effectiveness is lower where adherence lapses, so the 0.01 multiplier is a best-case figure for consistent daily/on-time use.
-
[4] aidsmap / NAM (Liz Highleyman) — Major disparities persist in lifetime risk of HIV diagnosis in the US
Major disparities persist in lifetime risk of HIV diagnosis in the US- Statistic
Overall lifetime HIV-diagnosis risk fell from about 1 in 78 (2004-2005) to 1 in 99 (2009-2013). Black gay/bisexual men 1 in 2; Latino gay men 1 in 4; white gay men 1 in 11. All MSM 1 in 6. Lifetime risk ranged from 1 in 670 (North Dakota) to 1 in 13 (Washington, DC).- Excerpt
“"The researchers found that the overall lifetime risk of an HIV-positive diagnosis was lower than it was a decade ago, falling from about 1 in 78 during 2004-2005 to 1 in 99 during 2009-2013... The lifetime risk estimate is the cumulative probability of being diagnosed with HIV from birth to death, assuming diagnosis rates remain constant." ”
- Source data from
- 2016-02-24
- Accessed
- 2026-06-21 · archived copy
- Calculation
- Secondary source covering the CROI 2016 presentation of the same CDC research line at the earlier 2009-2013 data window, where the overall figure was the widely cited "1 in 99". Used only to document the 1-in-99 historical framing and the time trend; the 2009-2013 subgroup figures (e.g. Latino MSM 1 in 4, DC 1 in 13) are NOT mixed into the published 2010-2014 source block above. Non-authoritative type; the three CDC/peer-reviewed sources carry the entry's authority requirement.